法律意见书 广东华商律师事务所 关于深圳市华盛昌科技实业股份有限公司 2023年第二次临时股东大会的 法律意见书 二○二三年九月十五日 1 法律意见书 致：深圳市华盛昌科技实业股份有限公司 广东华商律师事务所（以下简称"本所"）接受深圳市华盛昌科技实业股份 有限公司（以下简称"公司"）的委托，指派本所周玉梅律师、李世琦律师（以 下简称"本所律师"）出席公司2023年第二次临时股东大会（以下简称"本次会 议"）。本所律师依据《中华人民共和国证券法》（以下简称"《证券法》"）、 《中华人民共和国公司法》（以下简称"《公司法》"）、《上市公司股东大会 规则（2022年修订）》等法律、法规和规范性法律文件以及《深圳市华盛昌科技 实业股份有限公司章程》（以下简称"《公司章程》"）的规定，出具本法律意 见书。 本法律意见书仅对本次会议召集和召开的程序、出席本次会议人员的资格、 召集人资格及表决程序是否符合相关法律、法规和《公司章程》的规定以及本次 会议审议议案的表决结果是否有效进行核查并发表意见，并不对本次会议所审议 的议案内容以及该等议案所涉及的事实或数据的真实性和准确性发表意见。 本所律师同意将本法律意见书作为公司本 ...

证券代码：002980 证券简称：华盛昌 公告编号：2023-069 深圳市华盛昌科技实业股份有限公司 第三届董事会 2023 年第一次会议决议公告 本公司及公司全体董事会成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 深圳市华盛昌科技实业股份有限公司（以下简称"公司"）第三届董事会2023 年第一次会议通知于2023年9月13日以电子邮件、微信方式发出，并于2023年9月 15日下午15:00以现场及通讯相结合的方式在公司会议室召开。会议应出席董事8 人，实际出席董事8人，其中董事程鑫先生以通讯表决方式出席会议，会议由与 会董事共同推举的董事袁剑敏先生主持，公司监事及部分高级管理人员列席了会 议。本次会议的召开，符合《公司法》、《证券法》的相关规定。 二、董事会会议审议情况 经与会董事充分讨论与表决，通过了以下议案： 表决结果为：8 票同意，0 票反对，0 票弃权。 2、审议通过了《关于选举第三届董事会各专门委员会的成员及其召集人的 议案》 根据《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范 运作》（以下简称"《规范运作》"）、《上 ...

证券代码：002980 证券简称：华盛昌 公告编号：2023-067 深圳市华盛昌科技实业股份有限公司 关于使用闲置募集资金及闲置自有资金进行现金管理 到期赎回的公告 序 号 签约 银行 产品名 称 产品 类型 购买金额 （万元） 产品起 息日 产品到 期日 预计年化 收益率 是否 赎回 赎回本金 （万元） 投资收益 （元） 一、本次使用闲置募集资金进行现金管理到期赎回的情况 | | 招商 | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 银行 | | | | | | 1.55%，利率 | | | | | | 股份 | 7天通知 | 定期通 | | 2023年9 | 7天通 | 遇人民银行 | | | | | 1 | 有限 | 存款 | 知存款 | 16,000.00 | | 知 | 调整存款基 | 是 | 16,000.00 | 55,111.11 | | | 公司 | | | | 月5日 | | 准利率而相 | | | | | | 深圳 | | | | | | 应调整 | ...

备注：公司子公司与上表所列签约银行无关联关系，全部以闲置募集资金购买。 证券代码：002980 证券简称：华盛昌 公告编号：2023-065 深圳市华盛昌科技实业股份有限公司 关于使用闲置募集资金进行现金管理到期赎回的公告 本公司及公司全体董事会成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 深圳市华盛昌科技实业股份有限公司（以下简称"公司"）于2022年8月29 日召开第二届董事会2022年第四次会议、第二届监事会2022年第四次会议，2022 年9月15日召开2022年第三次临时股东大会，审议通过了《关于使用闲置募集资 金及闲置自有资金进行现金管理的议案》，同意公司及子公司在确保不影响正常 运营和募集资金投资项目建设的情况下，使用不超过3.5亿元（含本数）闲置募 集资金和不超过2亿元（含本数）闲置自有资金进行现金管理，上述额度自股东 大会审议通过之日起12个月内有效，在前述额度和期限范围内，可循环滚动使用。 闲置募集资金现金管理到期后将及时归还至募集资金专户。具体内容详见公司于 2022年8月31日、2022年9月16日在《中国证券报》、《证券时报》、《上海证券 报》、《证 ...

证券代码：002980 证券简称：华盛昌 公告编号：2023-064 深圳市华盛昌科技实业股份有限公司 关于使用闲置募集资金进行现金管理到期赎回的公告 本公司及公司全体董事会成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 深圳市华盛昌科技实业股份有限公司（以下简称"公司"）于2022年8月29 日召开第二届董事会2022年第四次会议、第二届监事会2022年第四次会议，2022 年9月15日召开2022年第三次临时股东大会，审议通过了《关于使用闲置募集资 金及闲置自有资金进行现金管理的议案》，同意公司及子公司在确保不影响正常 运营和募集资金投资项目建设的情况下，使用不超过3.5亿元（含本数）闲置募 集资金和不超过2亿元（含本数）闲置自有资金进行现金管理，上述额度自股东 大会审议通过之日起12个月内有效，在前述额度和期限范围内，可循环滚动使用。 闲置募集资金现金管理到期后将及时归还至募集资金专户。具体内容详见公司于 2022年8月31日、2022年9月16日在《中国证券报》、《证券时报》、《上海证券 报》、《证券日报》和巨潮资讯网（http://www.cninfo.com.cn） ...

Financial Performance - The company achieved operating revenue of CNY 327,194,591.74, a year-on-year increase of 2.29%[21] - Net profit attributable to shareholders was CNY 56,608,493.50, a decrease of 7.71% compared to the same period last year[21] - The company reported a significant increase in cash flow from operating activities, reaching CNY 71,144,917.98, compared to a negative cash flow of CNY -2,727,680.93 in the previous year, marking a 2,708.26% increase[21] - The gross profit margin improved to 40.51%, up 4.42% from the same period last year[24] - The company reported a total non-recurring gains and losses of 5,083,881.21, with government subsidies contributing 2,626,941.02[33] - The company’s main business revenue reached CNY 317.64 million, a year-on-year increase of 4.18%[110] - The gross profit margin for the main business was 40.70%, up 3.77% from the previous year[110] - Investment income amounted to CNY 642,852.92, contributing 1.06% to total profit, but is not sustainable[111] - The company reported a net loss from asset impairment of CNY 4.12 million, accounting for -6.77% of total profit[111] Revenue Growth - Revenue from medical testing products increased by 121.15% year-on-year, reaching CNY 19,526,800[22] - Revenue from new energy and related testing products surged by 167.33%, totaling CNY 19,312,100[22] - Domestic revenue grew by 61.40% year-on-year, amounting to CNY 52,865,600[22] - The medical testing segment saw a remarkable growth of 121.15%, with revenue rising to CNY 19.53 million from CNY 8.83 million[108] - The renewable energy and related testing segment experienced a growth of 167.33%, with revenue increasing to CNY 19.31 million from CNY 7.22 million[108] Research and Development - The company invested CNY 35,506,500 in R&D, a 23.49% increase compared to the previous year[24] - R&D investment reached 35.51 million, an increase of 6.75 million year-on-year, representing a growth rate of 23.49%[29] - R&D investment accounted for 10.85% of operating revenue, up from 8.99% in the same period last year, an increase of 1.86%[29] - The company is committed to increasing its R&D efforts in advanced technologies such as MEMS and smart sensor materials[39] - The company plans to enhance its molecular and immunodiagnostic platforms, focusing on the development of electrochemical detection technologies for rapid and precise diagnostics[74] Market Position and Strategy - The company is positioned as a leading comprehensive measurement and testing solution provider in the domestic market, focusing on product innovation and technology development[38] - The company aims to leverage the domestic market opportunities arising from the national policy of promoting domestic substitution in the instrumentation industry[39] - The company plans to expand its market presence by enhancing its product offerings in smart sensors, precision instruments, and high-end medical devices[39] - The company has identified significant growth potential in the domestic instrumentation market, which is currently dominated by foreign products[39] - The company is focusing on improving its manufacturing capabilities and product innovation in precision instruments and automation systems[39] Product Development and Innovation - The company has developed a series of innovative products, including a digital multimeter with an integrated thermal imaging function, which is a first in the domestic market[49] - The company has launched the RM190 radiation personal dose equivalent monitoring instrument, which features high sensitivity and is widely used in various radiation-related fields[60] - The company’s innovative temperature instruments and environmental detection products have seen significant sales growth compared to the same period last year, with large orders from key customers now in mass production[60] - The company has developed a high-precision +2.5℃ dew point temperature testing instrument, which is the only one of its kind in China, with a measurement range from -50℃ to 30℃ and a humidity measurement resolution of 0.01% RH[61] - The company has developed home medical devices, including blood pressure and temperature monitors, which have received medical certification and are part of a growing product matrix[68] Market Trends and Projections - The global testing instruments and equipment market is expected to grow from $34.3 billion in 2023 to $42.9 billion in 2028, with a compound annual growth rate of 4.6%[63] - The environmental monitoring market is projected to grow to $17.9 billion by 2026, driven by the company's continuous development of new products in response to market demands and the promotion of "dual carbon" goals[58] - The global in vitro diagnostics market exceeded USD 124 billion in 2022, with a projected CAGR of 6% from 2023 to 2028[71] - The global portable energy storage device shipment is expected to reach 31.1 million units by 2026, with China's share at 28.67 million units, and the global market size exceeding 80 billion yuan[78] - The household energy storage market saw a new installed capacity of 15.6 GWh in 2022, representing a year-on-year growth of 136.4%, with a projected cumulative installed capacity of 748.9 GWh by 2030[78] Corporate Governance and Shareholder Relations - The company has established a comprehensive internal control system to protect the rights of shareholders, especially minority shareholders, ensuring timely and accurate information disclosure[147] - The company actively participates in social responsibility initiatives, including donations to the Guangdong Zhong Nanshan Medical Foundation and support for rural revitalization activities[150] - The company has fulfilled all commitments made by its controlling shareholders and related parties during the reporting period, with specific commitments related to share lock-up and price stabilization completed by April 2023[153] - The company completed the initial grant registration of 3,021,500 restricted stocks under the 2022 restricted stock incentive plan on March 14, 2023[142] - The company has established partnerships with Southern University of Science and Technology and Guangdong University of Technology to advance sensor technology and industrialization[87] Risks and Challenges - The company faces risks from international trade policies and exchange rate fluctuations, which may impact future overseas business performance[132] - The company is addressing the risk of rising raw material prices by optimizing supply chain resources and enhancing cost control measures[133] - The company acknowledges competitive risks in the instrument and meter industry and plans to enhance product quality and management efficiency to maintain competitiveness[134] - The company has faced significant negative impacts on offline marketing network layout due to objective reasons since the end of 2019, affecting personnel recruitment and site leasing[125] Investments and Projects - The company invested CNY 691.43 million during the reporting period, a 4.10% increase compared to the previous year[117] - The total amount of raised funds was CNY 49.63 million, with CNY 15.72 million utilized by June 30, 2023, leaving CNY 29.70 million unutilized[122] - The company has plans to reduce the investment scale of the "Huashengchang Instrument and Meter Bazhong Production Base Construction Project" to 60 million yuan due to delays in construction and equipment installation[125] - The "Domestic Operation and Marketing Network Construction Project" will be terminated, and remaining funds will be redirected to the "Huashengchang Intelligent Sensing Measurement Instrument R&D Production Project" to address production bottlenecks[125] Shareholder Structure and Equity - The total number of ordinary shareholders at the end of the reporting period is 15,504[191] - Major shareholder Yuan Jianmin holds 52.80% of shares, totaling 72,000,000 shares, with a reduction of 54,000,000 shares released from restrictions[192] - The total number of restricted shares released during the period is 64,521,500 shares[189] - The company’s stock structure now includes a significant portion of unrestricted shares, improving market liquidity[183] - The completion of the incentive plan is expected to align employee interests with shareholder value, fostering long-term growth[182]

证券代码：002980 证券简称：华盛昌 公告编号：2023-055 深圳市华盛昌科技实业股份有限公司 第二届监事会 2023 年第三次会议决议公告 本公司及公司全体监事会成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 深圳市华盛昌科技实业股份有限公司（以下简称"公司"）第二届监事会2023 年第三次会议通知于2023年8月11日以电子邮件等方式发出，并于2023年8月23日 下午16:30以现场形式在公司会议室召开。会议应出席监事3人，实际出席监事3 人，会议由监事会主席钟孝条先生主持。本次会议的召开，符合《公司法》、《证 券法》的相关规定。 二、监事会会议审议情况 经与会监事充分讨论与表决，通过了以下议案： 1、审议通过了《关于公司2023年半年度报告全文及其摘要的议案》 经审核，监事会认为：董事会编制和审核深圳市华盛昌科技实业股份有限公 司2023年半年度报告的程序符合法律、行政法规和中国证监会的规定，报告内容 真实、准确、完整地反映了公司的实际情况，不存在任何虚假记载、误导性陈述 或者重大遗漏。 具体内容详见公司刊登在《证券时报》和巨潮资讯网（w ...

证券代码：002980 证券简称：华盛昌 公告编号：2023-060 深圳市华盛昌科技实业股份有限公司 特此公告。 深圳市华盛昌科技实业股份有限公司 监事会 2023 年 8 月 25 日 附件：公司第三届监事会非职工代表监事候选人简历 关于监事会换届选举的公告 本公司及公司全体监事会成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 深圳市华盛昌科技实业股份有限公司（以下简称"公司"）第二届监事会任 期即将届满，为保证监事会工作的有序开展，根据《中华人民共和国公司法》（以 下简称"《公司法》"）、《深圳证券交易所上市公司自律监管指引第1号——主板上 市公司规范运作》（以下简称"《规范运作》"）和《公司章程》的相关规定，公司 于2023年8月23日召开第二届监事会2023年第三次会议，审议通过了《关于公司 监事会换届选举非职工代表监事的议案》。 根据《公司章程》的规定，公司监事会由3名监事组成，其中非职工代表监 事2人，职工代表监事1人。经监事会审议同意提名钟孝条先生和何慧女士为公司 第三届监事会非职工代表监事候选人（非职工代表监事候选人简历详见附件）， 经股东大会审议通过后，将与 ...

深圳市华盛昌科技实业股份有限公司 独立董事提名人声明 提名人深圳市华盛昌科技实业股份有限公司董事会现就提名浦 洪为深圳市华盛昌科技实业股份有限公司第三届董事会独立董事候 选人发表公开声明。被提名人已书面同意出任深圳市华盛昌科技实 业股份有限公司第三届董事会独立董事候选人。本次提名是在充分 了解被提名人职业、学历、专业资格、详细的工作经历、全部兼职 等情况后作出的，本提名人认为被提名人符合相关法律、行政法规、 部门规章、规范性文件和深圳证券交易所业务规则对独立董事候选 人任职资格及独立性的要求，具体声明如下： 一、被提名人不存在《中华人民共和国公司法》第一百四十六 条等规定不得担任公司董事的情形。 √ 是 □ 否 如否，请详细说明：____________________________ 二、被提名人符合中国证监会《上市公司独立董事规则》规定的 独立董事任职资格和条件。 √ 是 □ 否 — 1 — 如否，请详细说明：______________________________ 五、被提名人担任独立董事不会违反《中华人民共和国公务员 法》的相关规定。 √ 是 □ 否 如否，请详细说明：______________ ...